Literature DB >> 32808743

ABCB11 deficiency presenting as transient neonatal cholestasis: Correlation with genotypes and BSEP expression.

Li-Ting Li1, Zhong-Die Li1, Ye Yang2, Yi Lu1, Xin-Bao Xie1, Lian Chen3, Jia-Yan Feng3, A S Knisely4, Jian-She Wang1,5.   

Abstract

BACKGROUND & AIMS: ABCB11 deficiency presenting in infancy is believed generally to manifest as persistent/progressive cholestasis. We describe a group of patients with biallelic ABCB11 variants whose disorder manifested as transient neonatal cholestasis (TNC).
METHODS: Neonatal intrahepatic cholestasis in 68 children (31 males) with biallelic predictedly pathogenic variants (PPV) in ABCB11 was classified as transient (TNC group, n = 23, 11 males), intermittent (benign recurrent intrahepatic cholestasis [BRIC] group, n = 3, 1 male) or persistent/ progressive (progressive familial intrahepatic cholestasis [PFIC] group, n = 42, 19 males). Clinical, genetic and bile salt export pump (BSEP) expression information was correlated with outcomes.
RESULTS: The median onset age of jaundice was 3 days (birth to 2 months) for the TNC group and 10.5 days (birth to 3 months) for the PFIC group (P = .034). The median length of follow-up of TNC patients was 44 months (12 months-168 months). At presentation, hepatobiliary-injury biomarker values were similar between the groups (P > .05). TNC patients (17/23) more often than PFIC patients (20/42, P = .041) harboured biallelic non-null variants (predicted not to terminate translation prematurely). TNC patient livers (7/7) more often than PFIC patient livers (5/16, P = .005) expressed immunohistochemically detectable BSEP. Kaplan-Meier analysis showed better prognosis for patients with BSEP expression (P = .009). Too few BRIC patients were available for statistical study.
CONCLUSIONS: Neonatal cholestasis associated with biallelic PPV in ABCB11 can resolve temporarily or persistently in one third of cases. Resolution is more likely in patients with biallelic non-null PPV or with liver BSEP expression.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990ABCB11zzm321990; cholestasis; genotype-phenotype

Mesh:

Substances:

Year:  2020        PMID: 32808743     DOI: 10.1111/liv.14642

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

Review 1.  Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3: Outcome and therapeutic strategies.

Authors:  Seema Alam; Bikrant Bihari Lal
Journal:  World J Hepatol       Date:  2022-01-27

2.  Identification of ABCC5 Among ATP-Binding Cassette Transporter Family as a New Biomarker for Hepatocellular Carcinoma Based on Bioinformatics Analysis.

Authors:  Yuting Qiu; Haobo Li; Jiaheng Xie; Xinwei Qiao; Jing Wu
Journal:  Int J Gen Med       Date:  2021-10-27

Review 3.  Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response.

Authors:  Ashwin Kamath; Suresh Kumar Srinivasamurthy; Mukta N Chowta; Sheetal D Ullal; Youssef Daali; Uppugunduri S Chakradhara Rao
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-11

4.  Guidelines for the Management of Cholestatic Liver Diseases (2021).

Authors:  Lungen Lu
Journal:  J Clin Transl Hepatol       Date:  2022-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.